Mindray Medical International
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Mindray Medical International's revenue will grow 19.1% and EPS will grow 11.9%.
The average estimate for revenue is $258.8 million. On the bottom line, the average EPS estimate is $0.47.
Last quarter, Mindray Medical International booked revenue of $219.0 million. GAAP reported sales were 21% higher than the prior-year quarter's $180.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.34. GAAP EPS of $0.31 for Q1 were 3.1% lower than the prior-year quarter's $0.32 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 54.9%, 20 basis points worse than the prior-year quarter. Operating margin was 16.8%, 150 basis points worse than the prior-year quarter. Net margin was 16.7%, 410 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.05 billion. The average EPS estimate is $1.76.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,359 members out of 1,395 rating the stock outperform, and 36 members rating it underperform. Among 255 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 241 give Mindray Medical International a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Mindray Medical International is outperform, with an average price target of $32.42.
- Add Mindray Medical International to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.